LP352 Emerging Drug Insight

“LP352 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about LP352 for Developmental and Epileptic Encephalopathy in the 7MM. A detailed picture of the LP352 for Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the LP352 for Developmental and Epileptic Encephalopathy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LP352 market forecast, analysis for Developmental and Epileptic Encephalopathy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Developmental and Epileptic Encephalopathy.

Drug Summary

LP352 is an oral, centrally acting, 5-HT2c superagonist in development for the potential treatment of seizures associated with DEEs such as Dravet syndrome, LGS, tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD), and other epileptic disorders. LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures. LP352 is the only 5-HTC receptor superagonist being dose-optimized for the refractory epilepsy population.

In the first quarter of 2022, the company started the Phase Ib/IIa Pacific Study. Additionally, the business intends to assess about 50 participants who have DEEs, including, but not limited to, Dravet syndrome, LGS, tuberous sclerosis complex, and CDKL5 deficient condition, and anticipates finishing the trial by the second half of 2023.

LP352 also demonstrated statistically significant reductions in both epileptiform event frequency and duration - reducing the frequency of epileptiform events by 85% and cumulative duration of epileptiform events by 84% in the SCN1lab zebrafish model of Dravet syndrome.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the LP352 description, mechanism of action, dosage and administration, research and development activities in Developmental and Epileptic Encephalopathy.
•  Elaborated details on LP352 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the LP352 research and development activity in Developmental and Epileptic Encephalopathy details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around LP352.
•  The report contains forecasted sales of LP352 for Developmental and Epileptic Encephalopathy till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Developmental and Epileptic Encephalopathy.
•  The report also features the SWOT analysis with analyst views for LP352 in Developmental and Epileptic Encephalopathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LP352 Analytical Perspective by DelveInsight

• In-depth LP352 Market Assessment

This report provides a detailed market assessment of LP352 in Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• LP352 Clinical Assessment

The report provides the clinical trials information of LP352 for Developmental and Epileptic Encephalopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

•  In the coming years, the market scenario for Developmental and Epileptic Encephalopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LP352 dominance.
•  Other emerging products for Developmental and Epileptic Encephalopathy are expected to give tough market competition to LP352 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LP352 in Developmental and Epileptic Encephalopathy.
•  Our in-depth analysis of the forecasted sales data of LP352 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LP352 in Developmental and Epileptic Encephalopathy.

Key Questions

•  What is the product type, route of administration and mechanism of action of LP352?
•  What is the clinical trial status of the study related to LP352 in Developmental and Epileptic Encephalopathy and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LP352 development?
•  What are the key designations that have been granted to LP352 for Developmental and Epileptic Encephalopathy?
•  What is the forecasted market scenario of LP352 for Developmental and Epileptic Encephalopathy?
•  What are the forecasted sales of LP352 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
•  What are the other emerging products available in Developmental and Epileptic Encephalopathy and how are they giving competition to LP352 for Developmental and Epileptic Encephalopathy?
•  Which are the late-stage emerging therapies under development for the treatment of Developmental and Epileptic Encephalopathy?